The US FDA Grants CytoSorbents Corporation (NASDAQ: CTSO) Conditional Approval for STAR-T Trial for Ticagrelor Removal during Cardiothoracic Surgery

CytoSorbents Corporation (NASDAQ: CTSO) has obtained approval of its investigational device exemption (IDE) application from the US Food and Drug Administration (FDA). The conditional approval will allow the company to carry out a controlled pivotal trial on STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) in the US. In addition, […]